Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.64 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427846 | 0.89 | P2RY12 (0.62) | HRH3P2RY12GPR119MAPTSMN1; SMN2 | |
| SCHEMBL31752774 | 0.86 | HRH3 (0.61) | HRH3GPR119 | |
| SCHEMBL3346693 | 0.83 | GPR119 (0.62) | HRH3GPR119NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL5213543 | 0.83 | HRH3 (0.61) | HRH3P2RY12MAPTMEN1ALDH1A1 | |
| SCHEMBL5210281 | 0.82 | HRH3 (0.77) | HRH3P2RY12 | |
| SCHEMBL1010764 | 0.82 | HRH3 (0.50) | HRH3P2RY12GPR119NPSR1MAPT | |
| SCHEMBL5781303 | 0.82 | HRH3 (0.55) | HRH3GPR119 | |
| SCHEMBL13128834 | 0.81 | HRH3 (0.61) | HRH3GPR119 | |
| SCHEMBL5212512 | 0.81 | HRH3 (0.61) | HRH3P2RY12ALDH1A1 | |
| SCHEMBL8085019 | 0.81 | P2RY12 (0.50) | HRH3P2RY12GPR119NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | HRH3 1/4885P2RY12 298/4885GPR119 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.